The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

AZN ASTRAZENECA PLC ORD SHS $0.25




 Page 4 of 5

Previous | 1 | 2 | 3 | 4 | 5 | Next

Time/Date Code Headline Source Impact
07:00 06-Mar-2017 AZN Directorate Change RNS +1.29% Up
07:00 03-Mar-2017 AZN ALLIANCE WITH SANOFI PASTEUR FOR MEDI8897 RNS +2.12% Up
16:30 01-Mar-2017 AZN Total Voting Rights RNS +2.89% Up
07:02 28-Feb-2017 AZN FDA approves once-daily Qtern for type-2 diabetes RNS +2.94% Up
12:32 24-Feb-2017 AZN CHMP positive opinion for ZS-9 in hyperkalaemia RNS +1.75% Up
07:00 20-Feb-2017 AZN AZ licenses Zoladex to TerSera for the US & Canada RNS -0.79% Down
07:00 17-Feb-2017 AZN Lynparza positive in metastatic BRCA breast cancer RNS -0.99% Down
12:01 16-Feb-2017 AZN SILIQ (BRODALUMAB) APPROVED BY US FDA RNS -1.53% Down
07:00 02-Feb-2017 AZN AZN: FY16 and Q4 2016 Results RNS +3.36% Up
16:00 01-Feb-2017 AZN Total Voting Rights RNS +2.17% Up
10:00 26-Jan-2017 AZN SYMBICORT GRANTED PAEDIATRIC EXCLUSIVITY IN THE US RNS -1.31% Down
07:00 17-Jan-2017 AZN AZ 1st-line lung cancer immuno-oncology programme RNS -3.58% Down
16:00 03-Jan-2017 AZN Total Voting Rights RNS +2.20% Up
07:00 23-Dec-2016 AZN AZ COMPLETES SALE OF ANTIBIOTICS BUSINESS RNS +1.82% Up
13:00 16-Dec-2016 AZN Director/PDMR Shareholding RNS +0.86% Up
15:05 09-Dec-2016 AZN FDA accepts durvalumab for BLA in bladder cancer RNS +6.21% Up
09:30 06-Dec-2016 AZN Tagrisso data shows superiority over chemotherapy RNS +0.40% Up
07:00 05-Dec-2016 AZN AZ completes agreement for Rhinocort Aqua rights RNS -1.47% Down
16:00 01-Dec-2016 AZN Block listing Interim Review RNS -4.46% Down
15:00 01-Dec-2016 AZN Total Voting Rights RNS -4.46% Down

 Page 4 of 5

Previous | 1 | 2 | 3 | 4 | 5 | Next



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.





Company Information
Updated Monthly
Company address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom
Company website http://www.astrazeneca....
Market cap(in millions)* £ 65,332.37
Listing/Admission to trading 01 Jun 1993
Trading service SETS
Market Main Market
Listing category Premium Equity Commercial Companies
*The market capitalisation of companies reflects the London listed element only. These figures are approximate and are updated monthly.

Trading Information
22-Oct-17
FTSE index FTSE All-Share,FTSE Eurotop 300,FTSE 350 High Yield,FTSE 100,FTSE 350 (ex IT),FTSE techMARK All-Share,FTSE All-Share (ex IT),FTSE 350
FTSE sector Pharmaceuticals & Biotechnology
FTSE sub-sector Pharmaceuticals
Country of share register GB
Segment SET0
MiFID Status Regulated Market
Exchange market size 500
SEDOL 0989529
ISIN number GB0009895292



ASTRAZENECA share news analysis (AZN)